Hormonal
The ER22/23EK polymorphism is associated with a lower risk of dementia, fewer white matter lesions, and significantly better survival rates in the elderly.
If you are elderly and carry the ER22/23EK variant, you have a genetic advantage for longevity and brain health. This variant is linked to lower dementia risk and better survival. Focus on maintaining this advantage through stress management and a healthy lifestyle, as your biology is naturally protected against the negative effects of cortisol on the brain.
At older age, we found that the risk of dementia and white matter lesions was lower in ER22/23EK carriers... we found in this population a significantly better survival in ER22/23EK carriers after a 4-year follow-up.
Why this rating
Based on large population-based studies with long-term follow-up (4 years) and statistically significant survival differences.
Source
Polymorphisms in the Glucocorticoid Receptor Gene and Their Associations with Metabolic Parameters and Body Composition
Elisabeth F. C. van Rossum · Recent Progress in Hormone Research · 2004
DOI 10.1210/rp.59.1.333
More from this paper
- The ER22/23EK polymorphism in the glucocorticoid receptor gene confers relative resistance to glucocorticoids, resulting in a healthier metabolic profile characterized by lower fasting insulin, increased insulin sensitivity, and lower cholesterol levels.Good
- The ER22/23EK polymorphism is associated with increased lean body mass and muscle strength in young adult males, and reduced abdominal fat measures in young adult females, due to relative glucocorticoid resistance.Good
- The N363S polymorphism is associated with increased glucocorticoid sensitivity, higher BMI, and increased insulin response to dexamethasone, though associations with BMI are controversial across different populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →